Bio-Manufacturing Market to be Grow by 7.72% CAGR during the forecast period
Increasing number of biopharmaceutical businesses and
growing demand for biopharmaceuticals is expected to drive the Global
Bio-Manufacturing Market growth in the forecast period, 2026-2030F.
According to TechSci Research report, “Bio-Manufacturing
Market – Global Industry Size, Share, Trends, Opportunity, and Forecast,
2020–2030F”, Global bio-manufacturing market stood at USD 19.08 billion
and is expected to grow at a CAGR of 7.72% through 2030. The biomanufacturing
market has witnessed remarkable growth in recent years, becoming a cornerstone
of the healthcare and biopharmaceutical industries. This dynamic field revolves
around the production of therapeutic products, vaccines, and other bio-based
substances through complex biological processes. This article delves into the
factors that are propelling the biomanufacturing market forward, shaping its
trajectory and influencing the future of healthcare innovation.
One of the primary driving forces behind the
biomanufacturing market is the increasing demand for biopharmaceutical
products. Biologics, which include monoclonal antibodies, vaccines, and
recombinant proteins, have gained prominence due to their specificity,
efficacy, and potential to address previously untreatable conditions. As the
global population faces mounting healthcare challenges, including chronic
diseases and viral outbreaks, the demand for innovative biopharmaceutical
solutions has surged, compelling biomanufacturing to expand its capabilities.
The continuous evolution of bioprocessing technologies has
revolutionized the biomanufacturing landscape. Cutting-edge techniques such as
continuous bioprocessing, single-use technologies, and automation have improved
production efficiency, reduced costs, and enhanced product quality. These
technological advancements have made biomanufacturing more scalable, adaptable,
and responsive to changing market demands.
The paradigm shift towards personalized medicine has
catalyzed the growth of biomanufacturing. With therapies tailored to an
individual's genetic makeup, biomanufacturing processes are adapting to produce
patient-specific treatments, including gene therapies and cell-based therapies.
The need for precise manufacturing processes to accommodate individual
variations is pushing the boundaries of biomanufacturing and shaping its future
trajectory.
Sustainable practices are gaining traction across
industries, including biomanufacturing. Companies are focusing on reducing
waste, optimizing resource usage, and adopting greener processes.
Biomanufacturing's potential to produce bio-based materials using renewable
resources aligns with these sustainability goals, making it an attractive
choice for both industry players and environmentally conscious consumers.
The biomanufacturing market's growth is driven by a
convergence of factors that are reshaping healthcare, technology, and industry
practices. The demand for innovative biopharmaceutical solutions, coupled with
advancements in technology, supportive regulations, and the pursuit of
sustainability, is propelling biomanufacturing to new heights. As the world
faces evolving healthcare challenges, biomanufacturing stands at the forefront,
poised to transform the way we develop, produce, and deliver life-saving therapies
to a global population in need.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Bio-Manufacturing Market”
The Global Bio-Manufacturing Market is segmented into
workflow, application, end user, regional distribution, and company.
Based on the workflow segment, continuous upstream biomanufacturing allows for continuous and steady production of biopharmaceuticals, eliminating the stop-start nature of traditional batch processes. This can lead to improved process efficiency, reduced downtime, and better resource utilization. The consistent environment and controlled conditions of continuous bioreactors can lead to higher cell densities and improved product yields compared to batch processes. Continuous biomanufacturing systems are often more compact than traditional batch systems, which can help in optimizing facility space and reducing operational costs. Continuous processes can result in more consistent and uniform product quality due to reduced variability and more precise process control.
Based on region, Asia-Pacific is the fastest-growing region
in the global bio-manufacturing market due to several key factors. Rapid
economic development, expanding healthcare infrastructure, and increasing
investment in biotechnology are driving regional growth. Countries like China,
India, South Korea, and Singapore are heavily investing in biomanufacturing
capabilities, supported by favorable government initiatives, tax incentives,
and public-private partnerships. The rising demand for biologics, including
vaccines, monoclonal antibodies, and gene therapies, is propelling
manufacturing expansion across the region. The availability of a skilled
workforce, lower production costs, and improved regulatory frameworks make
Asia-Pacific an attractive destination for outsourcing and contract
manufacturing.
Major companies operating in Global Bio-Manufacturing
Market are:
· Illumina
Inc.
· Thermo
Fischer Scientific Inc.
· Oxford
Nanopore Technologies plc
· Agilent
Technologies, Inc.
· BGI
Genomics Co. Ltd.
· PerkinElmer
Inc.
· QIAGEN
NV
· Eurofins
Scientific Inc.
· F.
Hoffmann-La Roche Ltd
· Takara
Bio Inc.
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The global bio-manufacturing market is experiencing robust
growth, driven by rising demand for biologics, vaccines, cell and gene
therapies, and biosimilars. Advancements in biotechnology, such as single-use
systems, automation, and continuous processing, are enhancing production
efficiency and scalability. Increasing prevalence of chronic diseases, an aging
population, and a strong pipeline of biologic drugs further support market
expansion. Government funding, favorable regulatory policies, and growing investments
from pharmaceutical companies are accelerating innovation and infrastructure
development. The shift toward personalized medicine and the expansion of
biomanufacturing capabilities in emerging markets contribute significantly to
the market's sustained global growth and future potential”, said Mr. Karan
Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“Bio-Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Workflow (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing), By Application (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Others), By End User (Biopharmaceutical Companies, Research Institutions, CMOs/CDMOs), By Region and Competition, 2020-2030F”, has
evaluated the future growth potential of Global Bio-Manufacturing Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Bio-Manufacturing Market.
Contact
TechSci Research LLC
420 Lexington Avenue,
Suite 300, New York,
United States- 10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com